Port-a-Cath Placement Complications

Overview

A totally implantable venous access port (TIVAP / port-a-cath) provides reliable long-term central venous access for chemotherapy, parenteral nutrition, blood products, and antibiotics. Overall reported complication rates range from about 2% to 14.4%, and are broadly lower with ultrasound-guided internal jugular vein (IJV) access and standardized protocols (Tabatabaie et al., American Journal of Clinical Oncology, 2017; Camargo et al., Scientific Reports, 2026). Complications are grouped by timing (intraoperative/immediate, early ≤30 days, late >30 days) and by anatomic origin (incision/pocket, catheter, reservoir/port).

Complication Categories and Reported Incidence

Complication Timing Reported incidence Key management Pneumothorax Intraoperative ~0.5–6% (higher with subclavian/landmark technique; ~0 with US + IJV) Observation vs. chest tube depending on size; US guidance largely eliminates risk Hemothorax Intraoperative Rare Drainage/chest tube; vascular repair if arterial laceration Arterial puncture (carotid ~3%, subclavian rarer) Intraoperative ~3% carotid Manual compression; vascular surgery if large-vessel injury Air embolism Intraoperative Rare Trendelenburg/left lateral position, 100% O2, aspiration Cardiac arrhythmia (guidewire/tip) Intraoperative Up to ~9% with tip migration Withdraw guidewire/reposition tip to cavoatrial junction Catheter malposition Early ~0.3% Fluoroscopic/endovascular repositioning (pigtail, gooseneck snare) Hematoma / pocket bleeding Early Low (minor) Compression; evacuation if expanding Wound dehiscence / skin erosion / port extrusion Early–late ~0.6% extrusion Wound care; often requires revision/explantation Infection (pocket, tunnel, exit site, CRBSI) Early–late (most common) ~1.5–5% pocket/site; CRBSI ~0.05–0.9/1000 catheter-days Systemic antibiotics ± antibiotic lock; removal for complicated infection Catheter-related thrombosis / venous stenosis Late Thrombosis ~0.3–28% (series-dependent); venous stenosis ~7% Anticoagulation; thrombolysis or removal in severe cases Catheter occlusion / fibrin sheath Late Variable Thrombolytic instillation (e.g., alteplase); fibrin sheath stripping Catheter fracture / disconnection / embolization Late Rare Endovascular retrieval; surgical revision Port flip / rotation Late Rare (single cases) Manual or surgical repositioning Extravasation Late Rare Stop infusion, aspirate, antidote per agent, surgical consult

Timing Patterns from Recent Cohorts

• Standardized US-guided IJV series (n=175): 100% procedural success, no early complications, 8.0% late complications (all skin ulceration around port/catheter). Concurrent diabetes + hypertension was the only independent risk factor (HR 12.2) (Ma et al., The American Surgeon, 2026).
• >1000 TIVAP series: No intraoperative/perioperative complications; 12% total complications (26.7% early, 73.3% late). Most common were infection (4.7%) and thrombosis (3.6%). Infectious complications carried the highest explantation rates; thrombotic complications were usually managed conservatively (Thiel et al., Langenbeck’s Archives of Surgery, 2022).
• Large oncology cohort (n=1180): 100% technical success; early events mostly minor (pain 24.7%, bruising 9.2%). Late: site cellulitis 3.8%, CRBSI 0.25%, thrombosis 0.25%, port extrusion 0.6% (Tashi et al., Annals of the Academy of Medicine, Singapore, 2024).
• Vascular surgeon image-guided series (n=443): No intraoperative/early complications; 2.0% late (infection, thrombosis, erosion, malfunction) (Kim, Journal of Surgical Research, 2025).
• Infection is both the most frequent and earliest category, with a steep early rise; catheter- and port-related events accrue more gradually (Tsuruta et al., Supportive Care in Cancer, 2020).

Management Principles

Infection

• Systemic antimicrobial therapy is the treatment of choice; device removal is required for complicated infection (tunnel/pocket infection, severe sepsis/septic shock, endocarditis, septic thrombophlebitis, osteomyelitis, hematogenous seeding).
• Infections due to S. aureus or Candida spp. generally warrant removal. Uncomplicated CRBSI not caused by these organisms may be treated conservatively with systemic antibiotics + antibiotic lock therapy.
• Remove if blood cultures remain positive 72 h after starting antibiotics (Lebeaux et al., The Lancet Infectious Diseases, 2014).
• Most guidelines cite ~0.3 infections/1000 catheter-days as an acceptable upper threshold (Walser, Cardiovascular and Interventional Radiology, 2012).

Thrombosis / occlusion

• Mechanical occlusions need cause-specific treatment; thrombotic occlusions usually resolve with thrombolytic instillation (e.g., alteplase).
• Catheter-related thrombosis: anticoagulation for ~6 weeks to a year depending on extent and persistence of risk factors; balance against bleeding/coagulopathy risk. Anticoagulation prophylaxis is not routinely recommended (Baskin et al., Lancet, 2009).
• Preventive measures: correct tip positioning at the cavoatrial junction and infection prevention.

Mechanical (fracture, migration, port flip)

• Endovascular retrieval/repositioning (pigtail catheter, gooseneck snare) under fluoroscopy; surgical revision or replacement for breakage or port separation (Wang et al., Current Medical Research and Opinion, 2025).

Local skin/pocket problems

• Port repositioning to a new pocket may salvage the device in selected local infections, avoiding full re-implantation (Sun et al., European Journal of Medical Research, 2025).

Prevention

• Ultrasound-guided venous puncture and fluoroscopic tip confirmation reduce pneumothorax, arterial injury, and malposition.
• Right IJV access is associated with lower rates of malposition, thrombosis, and pneumothorax than subclavian access.
• Operator experience matters: complication likelihood is roughly halved for operators with ≥50 insertions.
• Strict sterile access technique and standardized maintenance/locking protocols reduce CLABSI and occlusion.